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REVIEW
Abstract: In most patients with hypertension, especially Stage 2 hypertension, adequate
control of blood pressure (BP) is only achieved with combination drug therapy. When using
combination therapy, antihypertensive agents with complementary mechanisms of action are
recommended, for example, an angiotensin receptor blocker (ARB) in combination with
hydrochlorothiazide (HCTZ), a β-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium
channel blocker + an ACE inhibitor. One such combination is olmesartan medoxomil + HCTZ,
which is available as fixed-dose, single-tablet combinations for once-daily administration. In
clinical trials, olmesartan medoxomil/HCTZ reduced systolic BP (SBP) and diastolic BP (DBP)
to a greater extent than either component as monotherapy. A clinical study in patients with
Stage 1 or 2 hypertension showed that olmesartan medoxomil/HCTZ achieved a similar mean
reduction in DBP, but a significantly greater mean reduction in SBP and higher rate of BP
control (<140/90 mmHg) than observed with losartan/HCTZ, at US/European-approved starting
doses. In a non-inferiority trial, the antihypertensive efficacy of olmesartan medoxomil/HCTZ
was comparable to that of atenolol/HCTZ. Furthermore, indirect comparisons have shown
that olmesartan medoxomil/HCTZ compares favorably with other antihypertensive
combination therapies, including other ARB/HCTZ combinations and amlodipine besylate/
benazepril. Olmesartan medoxomil/HCTZ is generally well tolerated. In conclusion, olmesartan
medoxomil/HCTZ is an effective and well-tolerated combination antihypertensive therapy
that results in significant BP reductions and BP control in many patients.
Keywords: olmesartan medoxomil, hydrochlorothiazide, angiotensin II receptor blocker,
hypertension
Introduction
Hypertension is a highly prevalent cardiovascular risk factor, affecting an estimated
65 million people in the United States alone (American Heart Association 2006).
The control of blood pressure (BP) is important for the prevention of cardiovascular
morbidity and mortality; however, as many as two-thirds of patients do not have
their BP adequately controlled (Chobanian et al 2003). Treatment goals recommended
by the Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC 7) and international
guidelines are <140/90 mmHg, or <130/80 mmHg for patients with diabetes or chronic
renal disease (European Society of Hypertension 2003; Chobanian 2003; Whitworth
2003) In most patients, especially those with Stage 2 hypertension (systolic BP [SBP]
≥160 mmHg or diastolic [DBP] ≥100 mmHg), combination therapy is needed to
achieve adequate control of BP, and it is generally recommended that drugs with
complementary mechanisms of action should be used (Chobanian et al 2003).
Several fixed-dose combinations are now available, including β-blockers +
hydrochlorothiazide (HCTZ), ACE inhibitors + HCTZ, angiotensin receptor blockers
(ARBs) + HCTZ, and ACE inhibitors + calcium channel blockers. Many of these
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agents combine drugs with synergistic mechanisms of action
allowing for substantially greater reductions in BP compared
with component monotherapies. For example, patients are
more responsive to the BP-lowering effects of ARBs and
ACE inhibitors upon the addition of HCTZ. Although the
mechanism(s) involved are not clearly understood, HCTZ
may activate the renin-angiotensin system (RAS), making
BP more dependent on angiotensin II (Kjeldsen et al 2005).
These effects on counter-regulatory processes may help to
explain why the combination of an ARB or an ACE inhibitor
with HCTZ reduces BP more effectively than either agent
alone (Brown et al 1990; Chrysant 1994; Benz et al 1998;
Kochar et al 1999; Manolis et al 2000; Chrysant et al 2004).
Olmesartan medoxomil/HCTZ is the most recent fixed-
dose ARB/HCTZ combination to be approved for the
treatment of hypertension. This review will focus on the
pharmacodynamics, antihypertensive efficacy, and
tolerability of olmesartan medoxomil/HCTZ and how it
compares with other currently available fixed-dose
combinations.
Pharmacology of olmesartan
medoxomil and HCTZ
The clinical effects of angiotensin II, including
vasoconstriction, increasing intravascular volume, and
hormone secretion are mediated by AT1 receptors (Burnier
2001). Olmesartan medoxomil is an AT1 receptor antagonist,
demonstrating specificity for receptors in vascular tissue
(Mizuno et al 1995; Koike et al 2001). In vitro, olmesartan
medoxomil has been shown to be a competitive antagonist,
displaying high affinity, slow dissociation, and a high degree
of insurmountability for the AT1 receptor (Pugsley 2006).
The interaction of olmesartan with the AT1 receptor is
believed to occur via a two-step mechanism: the molecule
first undergoes a loose “surmountable” binding followed
by the formation of a tighter, “insurmountable” binding
complex. The slow dissociation of olmesartan medoxomil
from the AT1 receptor compares favorably with other ARBs’
dissociation, including telmisartan, and may contribute to
the antihypertensive efficacy of olmesartan medoxomil in
vivo (Pugsley 2006). The pressor response to exogenous
angiotensin I is inhibited to a clinically relevant extent
(>75%) by single doses of olmesartan medoxomil 10–40
mg, with substantial inhibition still apparent 24 hours after
dosing (Brunner and Nussberger 2001).
Thiazide diuretics such as HCTZ promote sodium
excretion, leading to a reduction in plasma volume and
peripheral resistance (Meredith 2005). The resulting
activation of the RAS means that the effect of blocking AT1
receptors and, therefore, the response to ARB therapy, is
enhanced, providing a rationale for co-administration of
agents from these two drug classes (Meredith 2005). Other
synergistic mechanisms are thought to be involved but are
not clearly understood. The increased efficacy resulting from
the combination of HCTZ with an ARB does not greatly
compromise the good tolerability profile of the ARB. The
combination of these two agents may permit the use of lower
doses of HCTZ and the ARB, which may be less likely to
result in adverse events typically associated with HCTZ use.
Olmesartan medoxomil is a pro-drug that is de-esterified
to its active metabolite, olmesartan, during absorption from
the gastrointestinal tract (Laeis et al 2001). Absorption is
rapid, with steady-state levels reached within 5 days (Laeis
et al 2001). Importantly, the long terminal elimination half-
life of 10–18 hours, coupled with minimal accumulation,
allows for once-daily dosing (Laeis et al 2001; Schwocho
and Masonson 2001). Systemically available olmesartan is
excreted via the kidneys and, after secretion in bile, in the
feces (Laeis et al 2001).
HCTZ is absorbed rapidly after oral administration and
is eliminated unchanged in the urine (Carter et al 2004;
Sweetman 2005). It has an elimination half-life of 8–15
hours after repeated doses, and the pharmacodynamic
response is sufficiently long to allow once-daily dosing
(Carter et al 2004). Clinically relevant pharmacokinetic
interactions do not occur between these two agents (Kreutz
et al 2006). Given both the pharmacokinetic and the
pharmacodynamic profiles of these agents, the combination
of olmesartan medoxomil with HCTZ is suitable for once-
daily administration in a single tablet.
Antihypertensive efficacy of
olmesartan medoxomil/HCTZ
A number of studies have provided evidence that the
combination of olmesartan medoxomil/HCTZ is an effective
option for antihypertensive therapy.
Comparison with monotherapy
A clinical trial using a randomized, double-blind, factorial
design showed that olmesartan medoxomil/HCTZ
combination therapy reduced DBP and SBP to a greater
extent than monotherapy with either component (Chrysant
et al 2004). In this study, hypertensive patients (n=502) with
a seated DBP of 100–115 mmHg were randomized to one
of 12 treatment groups for 8 weeks: olmesartan medoxomilVascular Health and Risk Management 2006:2(4) 403
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(10, 20, or 40 mg/day), HCTZ monotherapy (12.5 or 25 mg/
day), one of six groups of olmesartan medoxomil/HCTZ
combination therapy (covering each possible dosage
combination), or placebo.
A dose-dependent decrease in BP was seen across all
olmesartan medoxomil/HCTZ combinations compared with
the individual components, with the maximum mean
reduction of 26.8/21.9 mmHg observed with the highest-
dose combination, olmesartan medoxomil/HCTZ 40/25 mg/
day. After 8 weeks, mean reductions in seated DBP were
13.5–21.9 mmHg with combination therapy, compared with
11.3–14.6 mmHg with olmesartan medoxomil monotherapy
(10–40 mg/day), and 10.2–12.9 mmHg with HCTZ
monotherapy (12.5 or 25 mg/day). All combination and
monotherapy regimens reduced DBP and SBP significantly
more than placebo (Chrysant et al 2004).
The proportion of patients achieving a BP response
(defined as trough seated DBP <90 mmHg or a decrease
from baseline of ≥10 mmHg) increased in a dose-dependent
manner with each monotherapy and with combination
therapy, although between-group statistical comparisons
were not performed (Chrysant et al 2004). The response
rate was 92.3% for olmesartan medoxomil/HCTZ 40/25 mg/
day; diastolic control (trough seated DBP <90 mmHg) and
systolic control (trough seated SBP <140 mmHg) were
achieved in 79.5% and 87.2% of patients, respectively
(Chrysant et al 2004).
Additional support for combination therapy with
olmesartan medoxomil/HCTZ comes from a trial in
hypertensive patients with a seated DBP of 100–115 mmHg,
a seated SBP >150 mmHg, a 24-hour DBP ≥84 mmHg, and
at least 30% DBP daytime readings >90 mmHg. Mean seated
DBP remained ≥90 mmHg after 4 weeks of treatment with
olmesartan medoxomil 20 mg/day; however, the addition
of HCTZ 12.5 or 25 mg for 8 weeks significantly reduced
mean 24-hour DBP (–1.9 mmHg for HCTZ 12.5 mg,
p=0.0167; –3.7 mmHg for HCTZ 25 mg, p<0.0001) and SBP
(–3.8 mmHg for HCTZ 12.5 mg, p=0.0018; –7.4 mmHg for
HCTZ 25 mg, p<0.0001) compared with the addition of
placebo (Sellin et al 2005).
Evaluation of treatment algorithm
including olmesartan medoxomil/HCTZ
A stepwise treatment algorithm in which uptitration of
olmesartan medoxomil is followed by the addition of
increasing dosages of HCTZ is an effective option in patients
with Stage 1 or Stage 2 hypertension (Neutel et al 2004,
2006).
In this open-label, multicenter study (n=210), olmesartan
medoxomil 20 mg/day was initially administered for 4
weeks. Antihypertensive drug treatment was then uptitrated
at 4-week intervals until goal BP was achieved, progressing
through the following steps: uptitration to olmesartan
medoxomil 40 mg/day, addition of HCTZ 12.5 mg/day,
uptitration of HCTZ to 25 mg/day, addition of amlodipine
besylate 5 mg/day, and then uptitration of amlodipine
besylate to 10 mg/day (Neutel et al 2004, 2006). Endpoints
included the percentage of patients who achieved the BP
goal of ≤140/90 mmHg, and the more aggressive BP goal
of ≤130/85 mmHg. Those patients who achieved the more
aggressive BP goal at any time during the study exited the
trial.
The results of this study showed that a BP goal of ≤140/
90 mmHg and a more aggressive BP goal of ≤130/85 mmHg
could be achieved in many patients using a combination of
olmesartan medoxomil and HCTZ (Neutel et al 2004, 2006).
The goal of ≤140/90 mmHg was achieved in 83% of patients
after 8 weeks of dual combination therapy with olmesartan
medoxomil/HCTZ (titrated to 40/25 mg/day), while the goal
of ≤130/85 mmHg was attained in 69% (Neutel et al 2004).
Mean BP reductions and goal attainment rates for all patients
and for patients separated into those with Stage 1 or Stage 2
hypertension are shown in Figure 1. Looking specifically
at the SBP goal (≤140 mmHg), 96.2% of patients with Stage
1 hypertension (mean baseline SBP of 151.1 mmHg) and
78% of those with Stage 2 hypertension (mean baseline SBP
169.8 mmHg) achieved this goal (Neutel et al 2006). For
all patients combined after 8 weeks of treatment with
olmesartan medoxomil/HCTZ (titrated to 40/25 mg/day),
mean BP had decreased from baseline by 29.3/16.1 mmHg,
representing an incremental mean BP reduction of
approximately 11.6/5.4 mmHg beyond that achieved with
monotherapy. The addition of amlodipine besylate led to
further decreases in BP (Neutel et al 2004).
Comparison with other ARB/HCTZ
combinations
One direct comparison of olmesartan medoxomil/HCTZ
with another ARB/HCTZ combination has been published
recently. In this starting-dose, open-label comparison,
olmesartan medoxomil/HCTZ and losartan/HCTZ were
compared as initial therapy in patients with either newly
diagnosed Stage 2 hypertension or a DBP of 90–100 mmHg
despite treatment (Rump et al 2006). In this randomized,
double-blind, multicenter trial, patients were treated withVascular Health and Risk Management 2006:2(4) 404
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starting doses of each ARB (olmesartan medoxomil 20 mg/
day [n=308] or losartan 50 mg/day [n=305]) plus HCTZ
12.5 mg/day for 12 weeks. Mean BP reductions and BP
control rates (<140/90 mmHg) were compared after 1, 2, 4,
8, and 12 weeks of therapy; the primary endpoint was change
in DBP from baseline to 12 weeks. Olmesartan medoxomil/
HCTZ and losartan/HCTZ produced similar mean
reductions in DBP (–17.6 and –16.5 mmHg, respectively;
Figure 2). The mean reduction in SBP was 29.3 mmHg for
olmesartan medoxomil/HCTZ compared with 24.9 mmHg
for losartan/HCTZ (p≤0.0003). A significantly higher
percentage of olmesartan medoxomil/HCTZ recipients
achieved BP control (<140/90 mmHg) at week 12 compared
with losartan/HCTZ recipients (43.2% vs 32.1%, p=0.002)
(Rump et al 2006).
An indirect comparison of olmesartan medoxomil/HCTZ
with several other ARB/HCTZ combinations was performed
in a review of randomized, double-blind, placebo-controlled
factorial studies of similar design in hypertensive patients
with a DBP of 95–115 mmHg (Ram 2004). At maximum
US and European approved dosages, olmesartan
medoxomil/HCTZ compared favorably with irbesartan/
HCTZ, telmisartan/HCTZ, and valsartan/HCTZ, with each
combination producing double-digit reductions (not
placebo-adjusted) in both SBP and DBP (Table 1) (Ram
2004). DBP response rates (DBP<90 mmHg or a ≥10 mmHg
reduction from baseline) were numerically greater with
olmesartan medoxomil/HCTZ than telmisartan/HCTZ or
valsartan/HCTZ (eg, 92% vs 79% vs 81%; value not
reported for irbesartan) (Ram 2004).
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Figure 1 Antihypertensive efficacy of olmesartan medoxomil/HCTZ in patients with Stage 1 (SBP 140–159 mmHg or DBP 90–99 mmHg) and Stage 2 (SBP
≥160 mmHg or DBP ≥100 mmHg) hypertension. Data are from an open-label study (n=201) in which a stepwise treatment algorithm was followed, with titration at
4-weekly intervals until goal BP was achieved, when patients withdrew from the study (Neutel et al 2004, 2006). Eight weeks of monotherapy with olmesartan
medoxomil 20–40 mg/day was followed by 8 weeks of combination therapy with olmesartan medoxomil/HCTZ 40/12.5–25 mg/day. Reduction in BP and rate of
attainment of BP goals (≤140/90 mmHg and an aggressive goal of ≤130/85 mmHg) after 16 weeks are shown. (a) Mean BP reduction for patients in the combined
Stage 1/Stage 2 population treated with olmesartan medoxomil/HCTZ 40/12.5–25 mg/day (n=123) (Neutel et al 2004); (b) Cumulative goal attainment rates for the
combined Stage 1/Stage 2 population (Neutel et al 2004); (c) Cumulative mean BP reduction according to baseline stage of hypertension (Neutel et al 2006); (d)
Cumulative goal attainment rates according to baseline stage of hypertension (Neutel et al 2006). Cumulative results are based on the intent-to-treat population
using last observation carried forward, and include data for patients treated only with olmesartan medoxomil monotherapy as well as those treated with dual
combination therapy.
Abbreviations: DBP, diastolic BP; HCTZ, hydrochlorothiazide; SBP, systolic BP.Vascular Health and Risk Management 2006:2(4) 405
Olmesartan medoxomil/hydrochlorothiazide in hypertension
For indirect comparative purposes, data from a meta-
analysis (Conlin et al 2000) evaluating randomized
controlled trial data of several other ARB/HCTZ
combinations are presented in Table 2. All trials were in
hypertensive patients with a DBP of 95–115 mmHg, assessed
cuff BP, and used a similar definition of response rates (DBP
<90 mmHg or a decrease from baseline of ≥10 mmHg).
Combination therapy with HCTZ 12.5 mg/day plus starting
doses of candesartan, irbesartan, losartan, or valsartan was
associated with mean reductions in BP of 16.1–20.6/9.9–
13.6 mmHg and response rates of 56–70% when
administered at starting combination doses. In a trial of
eprosartan/HCTZ 600/12.5 mg/day which used similar
criteria as above, mean BP reductions of 9.2/10.7 mmHg
and a response rate (DBP<90 mmHg or within 90–
100 mmHg with a decrease of ≥10 mmHg) of 73% were
reported (Sachse et al 2002). Based on these indirect
comparisons, olmesartan medoxomil/HCTZ may achieve
BP response rates that compare favorably with other ARB/
HCTZ combinations at starting dosages (Table 2). However,
direct comparative studies are required to confirm these
findings.
Lastly, a study evaluating irbesartan/HCTZ in patients
with Stage 1 systolic hypertension (SBP 140–159 mmHg)
uncontrolled by monotherapy found that treatment with
irbesartan/HCTZ 300/25 mg/day led to a mean reduction in
BP of approximately 21.5/10.4 mmHg (from a mean baseline
BP of 154/91 mmHg), with 69% of patients reaching the
combined BP goal of <140/90 mmHg, and 77% achieving
SBP goal, after 18 weeks (Neutel et al 2005). In comparison,
in a trial discussed earlier, olmesartan medoxomil/HCTZ
40/25 mg/day reduced mean BP by 24.8/15.8 mmHg (from
a baseline of 151.1/94.7 mmHg) in patients with Stage 1
hypertension, and by 32.7/16.3 mmHg (baseline 169.8/
98.6 mmHg) in those with Stage 2 hypertension; SBP goal
(≤140 mmHg) was achieved in 96.2% and 78% of these
subgroups, respectively (Neutel et al 2006). Additional direct
comparative studies are now needed to more accurately
determine the comparative efficacy of olmesartan
medoxomil/HCTZ and other ARB/HCTZ combinations.
Comparison with other
antihypertensive combinations
Several clinical studies have compared the efficacy of
olmesartan medoxomil/HCTZ with other antihypertensive
combination therapies. For example, a study that compared
olmesartan medoxomil/HCTZ with atenolol/HCTZ found
that the antihypertensive efficacy of both combinations was
statistically comparable (Ball et al 2001). In this double-
blind, non-inferiority study, 328 patients with a mean seated
DBP of 100–120 mmHg receiving HCTZ 25 mg/day were
randomized to receive olmesartan medoxomil 10 mg/day or
atenolol 50 mg/day in addition to the HCTZ dose for 12
weeks, with dose-doubling after 4 weeks, if necessary.
Reductions in mean seated SBP and DBP (primary endpoint)
were 20.4/17.3 mmHg for olmesartan medoxomil/HCTZ
and 19.6/17.2 mmHg for atenolol/HCTZ. The upper limit
of the one-sided confidence interval (CI) for the between-
group difference for change in DBP (–0.08 mmHg; 90% CI
–1.17, 1.02) was within the prespecified least squares mean
limit of ≤3.5 mmHg, confirming that the efficacy of
olmesartan medoxomil/HCTZ was not inferior to atenolol/
HCTZ. The outcome was similar for SBP (between-group
difference –0.8 mmHg, 95% CI –2.61, 1.00) (Ball et al
2001).
Amlodipine besylate/benazepril is a well-established,
fixed-dose calcium channel blocker/ACE inhibitor
combination antihypertensive therapy. A direct comparison
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Figure 2 Antihypertensive efficacy of olmesartan medoxomil/HCTZ 20/12.5 mg/
day (n=308) compared with losartan/HCTZ 50/12.5 mg/day (n=305) as initial
therapy in patients with moderate to severe hypertension. Results of a
randomized, double-blind trial of 12 weeks’ treatment in 613 patients who had
either newly diagnosed hypertension with mean seated DBP 100–120 mmHg
and SBP ≥160 mmHg or inadequately controlled hypertension with DBP 90–
110 mmHg despite previous treatment (Rump et al 2006). (a) Reduction in mean
trough BP (DBP = primary endpoint); (b) Proportion of patients achieving BP
control (<140/90 mmHg) are shown for the intent-to-treat population.
*p=0.002, **p≤0.0003.
Abbreviations: DBP, diastolic BP; HCTZ, hydrochlorothiazide; LOS, losartan;
OLM, olmesartan medoxomil; SBP, systolic BP.Vascular Health and Risk Management 2006:2(4) 406
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between amlodipine besylate/benazepril and olmesartan
medoxomil/HCTZ has not been performed; however, an
indirect comparison of data from several factorial studies
(Quan et al 2006) suggests that mean reductions in seated
DBP may be quantitatively greater with olmesartan
medoxomil/HCTZ 40/25 mg/day than with amlodipine
besylate/benazepril 5/20 mg/day (approximately 22 vs
17 mmHg), whereas reductions in seated SBP appear similar
between the combinations (approximately 27 vs 27 mmHg)
(Quan et al 2006). The studies used similar designs and
enrolled patients with a baseline DBP of 100–115 mmHg.
However, a head-to-head trial is needed to properly compare
these combination therapies, and inclusion of the highest
available dosage of amlodipine besylate/benazepril 10/
20 mg (for which factorial study data were not available)
would be of interest.
Tolerability of olmesartan
medoxomil/HCTZ
Looking first at the individual components, an integrated
analysis of efficacy and safety demonstrated that the adverse
events profile observed with olmesartan medoxomil
monotherapy is similar to that seen with placebo, with
dizziness the only adverse event to occur in a significantly
greater number of olmesartan medoxomil patients compared
with placebo (2.8% vs 0.9%, respectively, p=0.01) (Neutel
2001). In comparison, HCTZ has been associated with
metabolic disturbances and electrolyte imbalances,
including hypokalemia and hyponatremia, particularly at
higher doses (Sweetman 2005). Physiological processes that
conserve sodium in the body, such as activation of the RAS,
produce an augmentation of renal potassium excretion
(Reyes 2002). Although clinical data are still lacking, it has
been suggested that the inhibition of the RAS resulting from
co-therapy with an ARB may reduce potassium loss, making
hypokalemia less of a potential problem among patients
receiving this combination (Kjeldsen et al 2005). In addition,
the tendency of HCTZ to elevate blood glucose levels and
promote type 2 diabetes mellitus may be offset with the use
of ARBs which have been shown to reduce the incidence of
new-onset diabetes as compared with β-blocker/HCTZ
therapy (Dahlof et al 2002).
Adverse events associated with the combination of
olmesartan medoxomil plus HCTZ are generally mild-to-
moderate in severity (Ball et al 2001; Chrysant et al 2004;
Neutel et al 2004; Rump et al 2006). Dizziness was reported
by more olmesartan medoxomil/HCTZ recipients than
placebo recipients in placebo-controlled trials, and was
associated with the addition of HCTZ (incidence 9% for
olmesartan medoxomil/HCTZ vs 2% for placebo vs 8% for
HCTZ monotherapy and 1% for olmesartan medoxomil
monotherapy) (Daiichi Sankyo, Inc. 2005). Upper
Table 1 Antihypertensive efficacy of angiotensin II receptor blocker/HCTZ combination therapies based on indirect comparison of
factorial studies of 8 weeks’ duration in hypertensive patients with a DBP of 95–115 mmHg. Results are shown for the starting and
the maximum approved dosages in the United States and Europe for each combination therapy (Benz et al 1998; McGill and Reilly
2001; Chrysant et al 2004; Ram 2004)
Treatment Dosage Mean absolute (placebo-subtracted) Absolute (placebo-
(mg/day)  reduction from baseline (mmHg)
a subtracted) response
rateb (%)
SBP DBP
Irbesartan/HCTZ  100/12.5
c 14.9 (12.6) 11.9 (8.4) –
300/25 23.1 (20.8) 14.4 (10.9) –
Olmesartan medoxomil/HCTZ 20/12.5 20.1 (16.8) 16.4 (8.2) 79 (41)
20/25
d 27.1 (23.8) 20.0 (11.8) 89 (51)
40/25
e 26.8 (23.5) 21.9 (13.7) 92 (54)
Telmisartan/HCTZ 40/12.5 18.8 (15.9) 12.6 (8.8) 63 (34)
80/12.5 23.9 (21.0) 14.9 (11.1) 79 (50)
Valsartan/HCTZ 80/12.5 16.5 (14.6) 11.8 (7.7) 64 (35)
160/25 22.4 (20.5) 15.3 (11.2) 81 (52)
aMean change in SBP and DBP at study end (or last observation carried forward) in the intent-to-treat population, except for the irbesartan study for which data are
for those completing the study and/or having a week 8 BP reading. Seated BP, except for the telmisartan study which reported supine readings.
bResponse defined as DBP <90 mmHg or a decrease from baseline of ≥10 mmHg.
cMarketed combination is 150/12.5 mg.
dMaximum in Europe.
eMaximum in United States.
Abbreviations: BP, blood pressure; DBP, diastolic BP; HCTZ, hydrochlorothiazide; SBP, systolic BP.Vascular Health and Risk Management 2006:2(4) 407
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respiratory tract infections were also more frequent with
olmesartan medoxomil/HCTZ than with placebo (7% vs 0%)
(Daiichi Sankyo, Inc. 2005).
Discussion
Although it is generally recommended that antihypertensive
therapy be initiated with a single agent, it is recognized that
most patients will eventually require combination therapy
to achieve recommended BP goals (Chobanian et al 2003;
European Society of Hypertension 2003; Whitworth 2003).
Indeed, JNC 7 suggests that in patients with Stage 2
hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg),
treatment should be initiated with two antihypertensive
agents (Chobanian et al 2003; European Society of
Hypertension 2003). Combination therapy typically consists
of drugs from different classes with complementary
mechanisms of action, such as a thiazide diuretic plus an
agent that acts on the RAS (European Society of
Hypertension 2003; Chobanian et al 2003).
Olmesartan medoxomil/HCTZ is one such combination,
and is available as fixed-dose, once-daily preparations
indicated for the treatment of hypertension, although not
indicated for first-line therapy. In clinical trials, olmesartan
medoxomil/HCTZ has demonstrated greater
antihypertensive efficacy than either component as
monotherapy (Chrysant et al 2004; Sellin et al 2005) and
appears to compare favorably with other ARB/HCTZ
combinations (Conlin et al 2000; McGill and Reilly 2001;
Sachse et al 2002; Ram 2004; Lacourciere et al 2005; Neutel
et al 2005; Rump et al 2006) and other fixed-dose
combinations from different antihypertensive drug classes
(Ball et al 2001; Quan et al 2006). However, limited head-
to-head trials suggest the need for additional comparative
trials in order to determine adequately potential differences
in the BP-lowering effects and BP goal attainment rates
achievable with these combination products.
It is well known that hypertension outcomes can be
improved in clinical practice by setting target BP goals and
providing physicians with easy-to-follow treatment
algorithms (Singer et al 2002; Neutel et al 2004). A target
level of <140/90 mmHg is recommended for patients with
uncomplicated hypertension and no evidence of diabetes
or renal disease (Chobanian et al 2003; European Society
of Hypertension 2003; Whitworth 2003). Importantly, in
an open-label trial, 9 out of 10 patients with Stage 1
hypertension, and more than half of patients with Stage 2
hypertension achieved an aggressive BP goal of ≤130/
85 mmHg when treated with olmesartan medoxomil/HCTZ
(Neutel et al 2006).
It is known that systolic hypertension is a better predictor
of future cardiovascular morbidity than diastolic
hypertension, especially in older patients (Izzo et al 2000;
European Society of Hypertension 2003). However, SBP is
often more difficult to control than DBP (Swales 1999;
Mancia et al 2002). Treatment algorithms based on
olmesartan medoxomil/HCTZ have been shown to
significantly reduce SBP, in addition to DBP, in patients
with Stage 1 and Stage 2 hypertension, allowing the majority
of patients in both groups to achieve the SBP goal of
≤140 mmHg (Neutel et al 2006).
Various factors affect compliance and persistency with
antihypertensive treatment. Long-term compliance has been
shown to be better if initial therapy is well tolerated and the
efficacy response is reasonably good (Caro et al 1999).
Table 2 Antihypertensive efficacy of other angiotensin II receptor blocker/HCTZ combinations based on indirect comparison
through a meta-analysis of randomized, double-blind, controlled trials assessing cuff BP in hypertensive patients with a DBP of 95–
115 mmHg. Results are shown for starting dosages in the United States or Europe for each combination (Conlin et al 2000). For
indirect comparative purposes, data for the starting dosage of olmesartan medoxomil/HCTZ from a randomized, double-blind,
controlled trial in patients with Stage 1 or Stage 2 hypertension are also tabulated (Chrysant et al 2004; Rump et al 2006)
Treatment Dosage Mean absolute reduction from Absolute response rateb
(mg/day) baseline (mmHg)
a (%)
SBP DBP
Candesartan/HCTZ  8/12.5 20.6 9.9 56
Irbesartan/HCTZ 150/12.5 16.1 12.4 66
Losartan/HCTZ 50/12.5 16.5 12.0 70
Valsartan/HCTZ 80/12.5 19.7 13.6 66
Olmesartan medoxomil/HCTZ
c 20/12.5 20.1 16.4 79
aWeighted average change in cuff SBP and DBP for the meta-analysis.
bResponse defined as DBP <90 mmHg or a decrease from baseline of ≥10 mmHg.
cResults from a trial with olmesartan medoxomil/HCTZ that was not part of the meta-analysis.
Abbreviations: DBP, diastolic BP; HCTZ, hydrochlorothiazide; SBP, systolic BP.Vascular Health and Risk Management 2006:2(4) 408
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Currently available once-daily, fixed-dose combinations,
such as olmesartan medoxomil/HCTZ and other ARB/HCTZ
combinations, may simplify treatment regimens. Olmesartan
medoxomil/HCTZ is effective and allows lower doses of
component agents to be used compared with monotherapy,
minimizing the likelihood of adverse events associated with
higher doses of HCTZ (Neutel 2001; Chrysant et al 2004).
These features may enhance patients’ acceptance of therapy
and potentially increase the likelihood that they will continue
with therapy through each successive stage of the treatment
algorithm.
In summary, olmesartan medoxomil/HCTZ is an
effective and well-tolerated combination antihypertensive
therapy. It provides greater antihypertensive efficacy than
either component given as monotherapy, and may provide
a useful treatment option in patients unable to achieve BP
goal with monotherapy.
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